Abstract: A uniaxial mounting for dispensing apparatus includes one or more uniaxial connecting portions on a dispenser and at least one support member having at least one complementary uniaxial mounting portion. The uniaxial mounting portions may include projections and generally complementary channels allowing rapid installation, removal and replacement of the dispenser. The support member may include a locking pivot for further adjustment capability. When dispensing heated liquids, a thermal insulator is incorporated to reduce heat conduction between the dispenser and the support member. The uniaxial mounting may have an alignment guide to ensure proper positioning of the dispenser along the axis of engagement between the uniaxial connecting portions.

Abstract: Glutamic acid derivatives in which the amino group is substituted with a 2-amino-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-ylalkyl-Z-carbonyl group, in which Z is a divalent, five-membered, nitrogen-containing heterocyclic ring system optionally containing a sulfur or nitrogen atom as a second hetero ring member, are antineoplastic agents. A typical embodiment is N-{3-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)e thyl]-pyrazol-5-ylcarbonyl}-L-glutamic acid.

Abstract: 4(3H)-X-7H-Pyrrolo[2,3-d]pyrimidines in which X is .dbd.O or .dbd.NH are prepared by treating a 6-amino-4(3H)-X-pyrimidine with a unsubstituted or substituted 1-nitroalk-1-ene to yield a 6-amino-4(3H)-X-pyrimidine which is substituted in the 5-position by a 1-nitroalk-2-yl group; (ii) converting the 5-(1-nitroalk-2-yl)-6-amino-4(3H)-X-pyrimidine to the corresponding 5-(1-oxoalk-2-yl)-6-amino-4(3H)-X-pyr-imidine; and (iii) removing the elements of water from the 5-(1-oxoalk-2-yl)-6-amino-4(3H)-X-pyrimidine to effect cyclization.

Abstract: A nozzle assembly (11) of an adhesive dispensing valve (10) includes a first valve (32) adjacent a discharge orifice (34). The first valve (32) opens to permit the flow of adhesive therethrough and closes to terminate the flow of adhesive in response to respective first and second states of the valve operating module (14). The adhesive dispensing valve (10) has a separable nozzle plate (102) that includes the first valve seat (100) and the discharge orifice (34) and is coupled to a nozzle body (72) with a mounting cap (104). A secondary valve (146) is located upstream of the first valve (32) and permits adhesive to flow therethrough in response to both of the first and second states of the valve operating module. However, as the mounting cap (104) and nozzle plate (102) are removed, the secondary valve (146) automatically engages its valve seat (94), thereby terminating the flow of adhesive while the nozzle plate (102) is removed from the valve body (16).

Abstract: 2-Amino-4-hydroxy-4,5,6,7-tetrahydropyrido?2,3-d!pyrimidine derivatives of aromatic amides, such as a benzamide or thienylcarboxamide in which the amino portion of the amide is other than L-glutamic acid are inhibitors of enzymes which utilize folic acid, in particular glycinamide ribonucleotide formyl transferase. A typical embodiment is N-(N-{4-?2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido?2,3-d!pyrimidin-6-y l)ethyl!benzoyl}-L-.gamma.-glutamyl)-D-aspartic acid.

Abstract: There are described heat-developable photosensitive image-recording elements which have an alkali-generating system incorporated therein. In the alkali-generating system, a slightly water-soluble metal compound is reacted with a salt of 2-hydroxy-pyridine-N-oxide, or its derivatives, in the presence of a fluid such as water, to form an insoluble precipitate and the alkali required for silver image development during processing. The image-recording materials are useful as image-forming materials in thermographic and photothermographic processes.

Abstract: A nozzle assembly (11) of an adhesive dispensing valve (10) includes a first valve (32) adjacent a discharge orifice (34). The first valve (32) opens to permit the flow of adhesive therethrough and closes to terminate the flow of adhesive in response to respective first and second states of the valve operating module (14). The adhesive dispensing valve (10) has a separable nozzle plate (102) that includes the first valve seat (100) and the discharge orifice (34) and is coupled to a nozzle body (72) with a mounting cap (104). A secondary valve (146) is located upstream of the first valve (32) and permits adhesive to flow therethrough in response to both of the first and second states of the valve operating module. However, as the mounting cap (104) and nozzle plate (102) are removed, the secondary valve (146) automatically engages its valve seat (94), thereby terminating the flow of adhesive while the nozzle plate (102) is removed from the valve body (16).

Abstract: Pyrido[2,3-d]pyrimidine compounds are prepared through the reaction of 2,4-diamino-6(1H)-pyrimidone and an activated derivative of a dialdehyde. A typical embodiment utilizes the dinitrile.

Abstract: N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]-pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-[4-(2-{4-hydroxy-6-aminopyrrolo-[2,3-d]pyrimidin-3-yl}ethyl)benzoyl]-L-g lutamic acid.

Abstract: 5-Substituted pyrrolo[2,3-d]pyrimidines are prepared from a nucleophile of the formula R.sup.2 -C(.dbd.NH)NH.sub.2 and a 2-amino-5-substituted-furan carrying a cyano or carboxy group in the 4-position. A typical example is the preparation of ethyl 4-(2-(2,4-diaminopyrrolo[2,3-d]pyrimidin-5-yl)ethyl}benzoate, an intermediate for the preparation of the known N-[4-{2-(2,4-diaminopyrrolo[2,3-d]pyrimidin-5-yl)ethyl}benzoyl]-L-glutamic acid, by allowing guanidine and ethyl 4-[2-(2-amino-3-cyanofur-4-yl)ethyl]benzoate to react under mild conditions.

Abstract: 3-Ethynylpyrrolo[2,3-d]pyrimidines are chemical intermediates for antineoplastic N-(acyl)glutamic acid derivatives. A typical embodiment is 3-ethynyl-4-hydroxy-6-pivaloylaminopyrrolo[2,3-d]pyrimidine.

Abstract: N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]-pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-{5-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)ethyl]thien-2-ylcar bonyl}-L-glutamic acid.

Abstract: 2,4-Diamino- and 2-amino-4-hydroxy- derivatives of N-(4-[2-(pyrido[2,3-d]pyrimidin-6-yl)alkyl]benzoyl-)-L-glutamic acids, and the corresponding 5,6,7,8-tetrahydro compounds are antineoplastic agents.The compounds are prepared by hydrolytic or hydrogenolytic removal of carboxylic acid protecting groups from the correspondingly protected glutamic acid derivatives.A typical embodiment is N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)e thyl]benzoyl)-L-glutamic acid.

Abstract: Substituted pyrimidin-5-yl derivatives of L-glutamic acid are anti-neoplastic agents. A typical embodiment is N-{4-[6-(2,6-diamino-4-hydroxypyrimidin-5-yl)hex-1-en-3-yl]benzoyl}-L-glut amic acid.

Abstract: N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-[4-(2-{4-hydroxypyrrolo[2,3-d]pyrimidin-3-yl}ethyl)benzoyl]-L-glutamic acid.

Abstract: 2-Amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-en-1-yl]pyrido[2,3,-d]pyrimid ines and 2-amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-yn-1-yl]pyrido[2,3-d]pyrimid ines are prepared through through the reaction of a haloaromatic compound and an unsaturated compound in the presence of a palladium catalyst. The products are chemical intermediates for the preparation of antineoplastic agents.A typical embodiment is the reaction of a protected 2-amino-4-hydroxy-6-ethynylpyrido[2,3-d]pyrimidine and an ester of 4-iodobenzoic acid.

Abstract: The diastereoisomeric forms of N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]-pyrimidin-6-yl) ethyl]benzoyl)-L-glutamic acid are antineoplastic agents.The compounds are prepared by separation of the diastereoisomeric form of the correspondingly protected glutamic derivatives and hydrolytic or hydrogenolytic removal of carboxylic acid and/or amino protecting groups.Typical embodiments are the (R,S) and (S,S) forms of N-(4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)e thyl]benzoyl)-L-glutamic acid.

Abstract: Pyrimidin-5-yl derivatives of L-glutamic acid are anti-neoplastic agents. A typical embodiment is N-(4-[5-(2,6-diamino-4-hydroxypyrimidin-5-yl)-butyl]-thien-2-ylcarboxy)-L- glutamic acid.

Abstract: 2-Amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-en-1-yl]pyrido[2,3,-d]pyrimid ines and 2-amino-4-hydroxy-6-[2-(4-carboxyphenyl)alk-1-yn-1-yl]pyrido[2,3-d]pyrimid ines are prepared through the reaction of a halo-aromatic compound and an unsaturated compound in the prosence of a palladium catalyst. The products are chemical intermediates for the preparation of antineo-plastic agents.A typical embodiment is the reaction of a protected 2-amino-4-hydroxy-6-ethynylpyrido[2,3-d]pyrimidine and an ester of 4-iodobenzoic acid.